Use of a combined form of prostate extract and alpha-adrenoblocker in patients after transurethral resection of the prostate

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Introduction. Prostate extract has pronounced anti-inflammatory and anti-androgenic properties, which contribute to a reduction in the volume of the prostate and an improvement in urination. Alpha-adrenoblockers, in turn, exert a relaxing effect on the smooth muscles of the bladder and prostate, thereby facilitating the urination. The combined use of these two drugs may provide a synergistic effect, leading to a pronounced improvement in quality of urination and accelerates recovery in patients after transurethral resection of the prostate. This approach may be more effective than using only one of these drugs.

Aim. To investigate the efficiency and safety profile of the prostate extract in combination with tamsulosin in patients after transurethral bipolar resection of the prostate.

Materials and methods. A total of 147 patients with benign prostatic hyperplasia (BPH) of stage II without severe concomitant diseases were included in the clinical study. The age of the men ranged from 48 to 81 years (61.7±1.4). All patients underwent transurethral bipolar resection of the prostate. Patients were randomized into two groups. In the main group, men received from the first postoperative day a combination of prostate extract with an alpha-adrenoblocker (prostate extract in powder 50 mg in terms of water-soluble peptides 10 mg and tamsulosin hydrochloride 0.4 mg) in the form of suppository after spontaneous bowel evacuation or enema daily for 30 days (n=70). In the control group, only alpha-adrenoblocker (tamsulosin 0.4 mg once a day for 30 days) in the postoperative period was given (n=77).

Results. In the main group, there was a reduction in the mean total IPSS score by 34.5% (p <0.05), and improvement in quality of life by 52% (p <0.05). The maximum urine flow rate increased by 69% (p <0.05), and the average urine flow rate increased by 94.6% (p<0.05). The positive effect on erectile function was 17.8% (p <0.05).

Conclusions. Our data allow to recommend this drug in the combined treatment of patients with benign prostatic hyperplasia (BPH) after transurethral resection of the prostate to restore urination function and improve quality of life.

全文:

受限制的访问

作者简介

Valentin Pavlov

Department of Urology and Oncology, Bashkir State Medical University of the Ministry of Health of Russia

Email: pavlov@bashgmu.ru
ORCID iD: 0000-0003-2125-4897

rector, Academician of the RAS, Ph.D., MD, professor, Head of the Department of Urology and oncology

 

俄罗斯联邦, 450008, Republic of Bashkortostan, Ufa, Zaiki Validi Street, 47

Albert Kazikhinurov

Department of Urology and Oncology, Bashkir State Medical University of the Ministry of Health of Russia

编辑信件的主要联系方式.
Email: alberturo@mail.ru
ORCID iD: 0000-0001-9284-7855

Ph.D., MD, professor of the Department of Urology and oncology

俄罗斯联邦, 450008, Republic of Bashkortostan, Ufa, Zaiki Validi Street, 47

Sabir Sabirzyanov

Department of Urology and Oncology, Bashkir State Medical University of the Ministry of Health of Russia

Email: sobir08-97@mail.ru
ORCID iD: 0000-0003-4044-0396

urologist

 

俄罗斯联邦, 450008, Republic of Bashkortostan, Ufa, Zaiki Validi Street, 47

Rustem Kazikhinurov

Department of Urology and Oncology, Bashkir State Medical University of the Ministry of Health of Russia

Email: royuro@mail.ru
ORCID iD: 0000-0001-6813-8549

Ph.D., MD, associate professor of the Department of Urology and oncology

俄罗斯联邦, 450008, Republic of Bashkortostan, Ufa, Zaiki Validi Street, 47

Rail Karaguzin

Department of Urology and Oncology, Bashkir State Medical University of the Ministry of Health of Russia

Email: railkaraggguzin@mail.ru
ORCID iD: 0009-0009-8034-3700

6-th year student

俄罗斯联邦, 450008, Republic of Bashkortostan, Ufa, Zaiki Validi Street, 47

参考

  1. Clinical recommendations of the Ministry of Health of the Russian Federation – Benign prostatic hyperplasia. 2020. https://cr.minzdrav.gov.ru/recomend/6_1. Russian (Клинические рекомендации Министерства Здравоохранения Российской Федерации – Доброкачественная гиперплазия предстательной железы. 2020. https://cr.minzdrav.gov.ru/recomend/6_1).
  2. Kuzmin I.V., Borovets S.Yu., Gorbachev A.G., Al-Shukri S.Kh. Prostatic bioregulatory polypeptide prostatilen: pharmacological properties and experience of 30 years of clinical use in urology. Urological statements. 2020;10:3. https://doi.org/10.17816/uroved4247.
  3. Kawahara T. Editorial Comment to Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia. Int J Urol. 2018;25(11):951–952. doi: 10.1111/iju.13798.
  4. Yin T., Qiao Z., Li Y., Li D., Jiang M., An C., Wang F., Zuo M., Hu K., Li Q.Comparisons of the Efficacy and Safety of Finasteride and Dutasteride for Benign Prostatic Hyperplasia: A Network Meta-Analysis. Am J Ther. 2017t;24(5):e517–e523. doi: 10.1097/MJT.0000000000000326.
  5. Lukyanov I.V. Benign prostatic hyperplasia. Modern treatment options. RMJ 2004;14:830. Russian (Лукьянов И.В. Доброкачественная гиперплазия предстательной железы. Современные возможности лечения. РМЖ. 2004;14:830).
  6. Gadzhieva Z.K., Alyaev Yu.G., Vinarov A.Z. On the peculiarities of the choice of drug therapy in obstructive diseases of the lower urinary tract. Effective pharmacotherapy. 2016;41:16–26. Russian (Гаджиева З.К., Аляев Ю.Г., Винаров А.З. Об особенностях выбора медикаментозной терапии при обструктивных заболеваниях нижних мочевыводящих путей. Эффективная фармакотерапия. 2016;41:16–26).
  7. Kuz’min I.V. Vitaprost Forte in the treament of patients with benign prostatic hyperplasia: pathogenetic basics and clinical results. Urologiia 2019;(4):141–147 DOI: https://dx.doi.org/10.18565/urology.2019.4.141-147. Russian (Кузьмин И.В. Витапрост Форте в лечении пациентов с доброкачественной гиперплазией простаты: патогенетические механизмы и клинические результаты. Урология. 2019;(4):141–147 DOI: https://dx.doi.org/10.18565/urology.2019.4.141-147).
  8. Osmonbekova N.S., Kurbanov F.S., Dobrovolsky S.R. The significance and methodology of analyzing the quality of life of surgical patients. Surgery. Journal named after N.I. Pirogov. 2012;5:84–87. Russian (Осмонбекова Н.С., Курбанов Ф.С., Добровольский С.Р. Значение и методика анализа качества жизни хирургических больных. Хирургия. Журнал им. Н.И. Пирогова. 2012;5:84–87).
  9. Kuzmenko A.V., Vinnik YU.YU., Kuzmenko V.V., Gyaurgiev T.A. The use of bioregulatory peptides in the treatment of men with benign prostatic hyperplasia and chronic prostatitis. Urologiia. 2021;(3):70–74. DOI: https://dx.doi.org/10.18565/urology.2021.3.70-74. Russian (Кузьменко А.В., Винник Ю.Ю., Кузьменко В.В., Гягирев Т.А. Применение биорегуляторных пептидов в лечении мужчин с доброкачественной гиперплазией простаты и хроническим простатитом. Урология 2021;(3):70–74) DOI: https://dx.doi.org/10.18565/urology.2021.3.70-74.
  10. Alberts B., Bray D., Lewis J., Raff M., Roberts K. Watson J. D. Molecular biology of the cell: In 3 vols. 2nd ed. Pererab. M75 and additional Vol.2: Translated from English-Moscow: Mir, 1993; 539.
  11. Ergakov D.V, Martov A.G. Use of vitaprost (tablets and rectal suppositories) for patients’ rehabilitation after invasive diagnostic urological interventions. Urologiia. 2015;(6):20–25. Russian (Ергаков Д.В., Мартов А.Г. Применение Витапроста (таблетки и ректальные суппозитории) для реабилитации пациентов после инвазивных урологических вмешательств. Урология. 2015;(6):20–25).
  12. Lau J.L., Dunn M.K. Therapeutic peptides: Historical perspectives, current development trends, and future directions Bioorganic & Medicinal Chemistry. 2018;26.
  13. Martov A.G., Ergakov D.V. Application of rectal suppository vitaprost plus before and after transurethral resection of the prostate. Urologiia 2013;(2):83–88. Russian (Мартов А.Г., Ергаков Д.В. Применение ректальных суппозиториев Витапрост Плюс до и после трансуретральной резекции предстательной железы. Урология. 2013;(2):83–88).
  14. Ergakov D.V., Martov A.G., Turin D.E. Use of cytomedins in case of prostatic involvement in chronic prostatitis according to upoint classification. Urologiia. 2019;(3):31–35. Russian (Ергаков Д.В., Мартов А.Г. Применение цитомединов при хроническом простатите с использованием классификации UPOINT. Урология. 2019;(3):31–35).
  15. Lee C.L., Kuo H.C. Current consensus and controversy on the diagnosis of male LUTS/BPH. Ci Ji Yi Xue Za Zhi (Tzu Chi Medical Journal). 2017;29(1):6–11.
  16. ElJalby M, Thomas D, Elterman D, Chughtai B. The effect of diet on BPH, LUTS and ED. World J Urol. 2019;37(6):1001–1005.
  17. Kumachev K.V., Logvinov L.A. The effectiveness of prostate extract in the treatment of patients with chronic prostatitis caused by intracellular pathogens. State budgetary healthcare institution «City Polyclinic No. 69 of the Moscow Department of Health». https://doi.org/10.21518/2079-701X-2019-12-160-165. Russian (Кумачёв К.В., Логвинов Л.А. Эффективность экстракта простаты в лечении больных хроническим простатитом, обусловленным внутриклеточными патогенами. Государственное бюджетное учреждение здравоохранения «Городская поликлиника № 69» Департамента здравоохранения г. Москвы. https://doi.org/10.21518/2079-701X-2019-12-160-165).
  18. Glybochko P.V., Alyaev Yu.G., Rapoport L.M., Enikeev D.V., Akhvlediani N.D., Spivak L.G., Chernov Ya.N., Laukhtina E.A., Dymova A.V., Taratkin M.S. Erectile function after endoscopic surgery for prostatic hyperplasia removal. Andrology and Genital Surgery. 2017;18(4):12–18. doi: 10.17650/2070-9781-2017-18-4-12-18.
  19. Pavlov VN, Kazikhinurov AA, Kazikhinurov RA, Sabirzyanov SS, Saleeva YD, Kazikhinurova KA. The use of prostate extract preparations in patients after transurethral resection of prostate for its benign hyperplasia. Urologiia. 2022;(6):42-46. doi: 10.18565/urology.2022.6.42-46. Russian (Павлов В.Н., Казихинуров А.А., Казихинуров Р.А., Сабирзянов С.Ш., Салеева Ю.Д., Казихинурова К.А. Применение препарата экстракта простаты у пациентов после трансуретральной биполярной резекции по поводу доброкачественной гиперплазии. Урология. 2022;(6):42-46. doi: 10.18565/urology.2022.6.42-46).

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2025